Program
ulotaront
Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.
Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.
Drug pageSEP-363856: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 265 open or running | phase 3since Aug 26, 2019 | Oct 24, 2013 | Mar 2028phase 3 · NCT07225712 |
| Sumitomo Pharmaits history only | 40 open or running | phase 3since Mar 29, 2021 | Nov 22, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Oct 24, 2013.
- Oct 2, 2019Phase 3 study in SchizophreniaNCT04115319 · 305 enrolled · United States, Romania, Russia and more
- Apr 27, 2020Phase 1 study in SchizophreniaNCT04369391 · 150 enrolled · United States
- Dec 19, 2020Named ulotarontINNProposed as its International Nonproprietary Name in WHO's List 124 · before, SEP-363856, SEP363856
- Apr 26, 2021Phase 1 study in SchizophreniaNCT04865835 · 21 enrolled · United States
- Aug 10, 2021Phase 1 study in NarcolepsyNCT05015673 · 18 enrolled · United States
- May 24, 2022Phase 1 study in SchizophreniaNCT05402111 · 31 enrolled · United States
- Jul 6, 2022Phase 1 study in SchizophreniaNCT05463770 · 15 enrolled · United States
- Aug 15, 2022Phase 1 study in SchizophreniaNCT05542264 · 19 enrolled · United States
- Oct 10, 2022Phase 2 study in Depressive Disorder, MajorNCT05593029 · 929 enrolled · United States, Bulgaria, Canada and more
- Nov 16, 2022Phase 3 study in SchizophreniaNCT05628103 · 101 enrolled · United States
- Feb 6, 20232 phase 3 studiesNCT05729373, NCT05741528
- Apr 27, 2023Phase 1 study in SchizophreniaNCT05848700 · 60 enrolled · United States
- Feb 27, 2025Phase 3 study in SchizophreniaNCT06894212 · 538 enrolled · United States, Japan
- Nov 5, 2025Phase 3 study in SchizophreniaNCT07225712 · 100 planned · Japan
- Aug 6, 20263 phase 3 studies in Generalized Anxiety DisorderNCT07759128, NCT07767903, NCT07786454
Ahead
- Mar 2028Primary completion: phase 3 study in SchizophreniaNCT07225712
- Oct 25, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07767903
- Dec 6, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07759128
- May 26, 2029Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07786454
TargetBeta
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule
Studies
All 26 Otsuka leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07786454Generalized Anxiety Disorder · United States | 3 | Recruiting | May 26, 2029 | 1,120 |
| NCT07767903Generalized Anxiety Disorder · United States | 3 | Recruiting | Oct 25, 2028 | 384 |
| NCT07759128Generalized Anxiety Disorder · United States | 3 | Recruiting | Dec 6, 2028 | 576 |
| NCT07225712Schizophrenia · Japan | 3 | Recruiting | Mar 2028 | 100 |
| NCT06894212Schizophrenia · United States, Japan | 3 | Active, not recruiting | Oct 20, 2026 | 538 |
| NCT05848700Schizophrenia · United States | 1 | Completed | Mar 15, 2024 | 60 |
| NCT05741528Schizophrenia · United States | 3 | Completed | Sep 23, 2024 | 75 |
| NCT05729373Generalized Anxiety Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | Sep 26, 2025 | 434 |
| NCT05628103Schizophrenia · United States | 3 | Completed | Apr 1, 2024 | 101 |
| NCT05593029Depressive Disorder, Major · United States, Bulgaria, Canada and more | 2 | Completed | Nov 6, 2025 | 929 |
| NCT05542264Schizophrenia · United States | 1 | Completed | Feb 12, 2024 | 19 |
| NCT05463770Schizophrenia · United States | 1 | Completed | Aug 22, 2023 | 15 |
| NCT05402111Schizophrenia · United States | 1 | Completed | Sep 27, 2023 | 31 |
| NCT05015673Narcolepsy · United States | 1 | Completed | May 26, 2015 | 18 |
| NCT04865835Schizophrenia · United States | 1 | Completed | May 3, 2022 | 21 |
| NCT04369391Schizophrenia · United States | 1 | Completed | Nov 10, 2020 | 150 |
| NCT04115319Schizophrenia · United States, Romania, Russia and more | 3 | Completed | Dec 30, 2022 | 305 |
| NCT04109950Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Terminated | Nov 9, 2023 | 463 |
| NCT04092686Schizophrenia · United States, Bulgaria, Croatia and more | 3 | Completed | Jun 14, 2023 | 464 |
| NCT04072354Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Completed | May 12, 2023 | 463 |
| NCT04038957Schizophrenia · United Kingdom | 1 | Completed | Jun 6, 2023 | 22 |
| NCT02970929Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Jan 29, 2019 | 157 |
| NCT02969369Parkinson Disease Psychosis · United States | 2 | Completed | Apr 20, 2020 | 39 |
| NCT02969382Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Jul 31, 2018 | 245 |
| NCT01994473Schizophrenia · United States | 1 | Completed | Dec 2014 | 48 |
| NCT01972711Schizophrenia · United Kingdom | 1 | Completed | Jul 2015 | 105 |
How it is read
Names in the registry
- “SEP-363856”, 24 entries
- “SEP-363856 75mg”, 2 entries
- “SEP363856”, 2 entries
- “SEP-363856 100mg”, 1 entry
- “SEP-363856 50mg”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 23 studies
- Generalized Anxiety Disorder, 4 studies
- Depressive Disorder, Major, 1 study
- Parkinson Disease, 1 study
- Narcolepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.